Atlas Trials

Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)

Clinical trial NCT05549284 · UNKNOWN

Trial details

NCT number
NCT05549284
Sponsor
Affiliated Hospital to Academy of Military Medical Sciences
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Primary Central Nervous System Lymphoma
Start date
2022-06-01
Primary completion
2023-05-30
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.